ClinicalTrials.gg
RecruitingNCT07397845SPARX RCTUpdated Jun 1, 2026

Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial

An interventional study of Protégé and Protégé NC and Agent in Coronary Artery Disease, Drug Eluting Balloon and Drug Eluting Stent, sponsored by Translumina GmbH. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Translumina GmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.

Planned enrollment
34th of 125
1,380 · median 296
Started
2026
with 6 others
No phase
78 of 177
14 open now
Primary completion
2028-04
later than 22 of 40 live
Registered
170th of 177
by date

Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 34th largest by planned enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2026, is one of 78 with no phase, reaches primary completion later than 22 of the 40 other live ones, and was the 170th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Coronary Artery Disease with a site in Switzerland, or all of them as a file.
02

Study summary

The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two different paclitaxel-coated balloons, Protégé and Agent, with each other.

Read the detailed description

PCI with DES remains a cornerstone of interventional cardiology for the treatment of coronary artery disease. While DES have significantly improved outcomes compared to plain old angioplasty (POBA) and metal stents, there is still a risk of in-stent restenosis (ISR) and stent thrombosis (ST). To overcome these problems, non-stent techniques using only DCBs have emerged as a way of delivering anti-proliferative drugs to the vessel wall without the need for a permanent implant. It is hypothesised that this approach may promote positive remodelling and reduce the risk of vessel thrombosis and restenosis.

The use of PCI with DCB alone was first investigated for the treatment of ISR, where it showed good results and is currently recommended in guidelines for the treatment of ISR. There have also been several DCB trials in de novo coronary lesions, but the results have been more mixed. Many DCBs are now commercially available, both with paclitaxel and sirolimus coating, and it appears that there is no "class effect" due to the heterogeneity that exists within balloon designs, polymer coating, type of drug and concentrations used.

One of the first trials in de novo lesions, the PICCOLETO trial, was stopped early due to a higher MACE rate in the DCB group compared to the DES group. However, several weaknesses of the study may explain the worse outcome in those treated with DCBs compared to DES. The most important was probably the low dose of paclitaxel delivered by the balloon and the fact that only a small percentage of the population underwent lesion predilatation. Several studies have later shown non-inferiority of DCB to DES for de novo lesions, and the method is currently embraced by the interventional cardiology community.

Several DCBs are now available and approved for use, and more are on the way, but head-to-head data are scarce. The SPARX trial is designed to compare two DCBs, Protégé™ and Agent™, with conventional DES PCI in complex and small coronary lesions, with the idea that this type of coronary disease may benefit from a DCB-only technique. The trial will also compare the two certified and well-established paclitaxel-coated balloons, Protégé™ and Agent™. The hypothesis is that Protégé™ will perform at least as well as Agent™.

The primary objective of the SPARX trial is to compare paclitaxel-coated balloons with contemporary DES in complex and small coronary artery lesions in patients with non-ST elevation acute coronary syndrome (NSTEACS) or chronic coronary syndrome (CCS); The co-primary objective is to compare 2 different paclitaxel-coated balloons, Protégé™ and Agent™, with each other.

03

Conditions studied

  • Coronary Artery Disease
  • Drug Eluting Balloon
  • Drug Eluting Stent

Keywords

  • SPARX RCT
  • Protege
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical inclusion criteria:

  1. Age≥18 years
  2. Patient with NSTE-ACS or CCS with either symptoms and/or ischemia on non-invasive or invasive testing (i.e. FFR/iFR, CMR, SPECT, PET-CT or stress-echo)
  3. The patient must be able to understand and provide written and comply with all study procedures
  4. of > 2 years

    Angiographic inclusion criteria:

  5. One or more trial target vessel (LAD, CX or RCA, or of their branches) with:

    1. Stenosis of ≥70% or
    2. Stenosis ≥50% and \<70% (visually assessed) with evidence of ischemia by positive stress test, or FFR ≤0.80, or iFR \<0.90 or IVUS minimum lumen area ≤4.0 mm2
  6. The target vessel/target lesion matches at least one of the following criteria

    1. Small vessel: vessel reference diameter is ≤ 3 mm
    2. Long lesions: length ≥ 25 mm
    3. Calcified lesion: grade 3 by angiography or confirmed on intravascular imaging
    4. Chronic total occlusion (CTO)
    5. Bifurcation lesions, including ostial LAD and ostial CX
    6. Lesions in diabetic coronary artery disease
    7. In-Stent Restenosis (ISR)
  7. Lesion preparation must be according to the 3rd DCB consensus, with lesions that have:

    1. ≤ 30% residual stenosis
    2. TIMI (Thrombolysis in Myocardial Infarction) flow grade 3.
    3. The absence of flow-limiting dissection (Type A-C allowed only)

Clinical exclusion criteria:

  1. STEMI or cardiogenic shock related to an acute MI within 2 days prior to the index PCI
  2. Pregnancy or nursing declarations (As per country specific guideline) (a negative pregnancy test is required of women with within 7 days prior to enrollment)
  3. \<30%
  4. Known or to any limus family drugs, paclitaxel, or to medications such as heparin, aspirin, clopidogrel, ticlopidine, prasugrel and ticagrelor or any component of the devices.
  5. Allergy to imaging contrast media which cannot be adequately pre-medicated
  6. Stroke/ during the last 6 months, or any prior intracranial hemorrhage
  7. Active peptic ulcer or upper gastrointestinal bleeding within last 6 months
  8. Known renal insufficiency with an \<30 ml/min1.73m2, or subject on dialysis, or acute renal failure (as per physician judgment)
  9. Planned surgery within 6 months with the necessity to stop DAPT
  10. History of bleeding diathesis or coagulopathy
  11. count\<100.000 cells/mm3 or >400.000 cells/mm3, a WBC of \<3000 cells/mm3, documented or suspected liver disease (including laboratory evidence of hepatitis)
  12. Patient is a recipient of a heart transplant
  13. Participation in another investigation with an drug or another MD within the 30 days preceding and during the present investigation

    Angiographic exclusion criteria:

  14. Target lesion is in the left main coronary artery
  15. Target lesion is in a coronary artery bypass graft
  16. Flow limiting target vessel thrombus
  17. Evidence of aneurysm in target vessel within 10 mm of the target lesion
  18. Aorto-ostial target lesion (within 3 mm of the aorta junction)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,380 participants (estimated)

Study arms

  • Experimental
    Paclitaxel coated balloon

    Patients are only randomized after successful lesion preparations performed as per the the 3rd DCB Consensus. Post this, if the automatic generation of the device reflects Protege on the opted platform, then the patient is enrolled in this arm of the RCT

    Device: Protégé and Protégé NC

  • Active comparator
    Drug coated balloon

    Patients are only randomized after successful lesion preparations performed as per the the 3rd DCB Consensus. Post this, if the automatic generation of the device reflects Agent on the opted platform, then the patient is enrolled in this arm of the RCT

    Device: Agent

  • Active comparator
    Drug eluting stent (DES)

    DES to standard of care treatment during percutaneous coronary intervention. In this RCT, patients are only randomized after successful lesion preparations performed as per the the 3rd DCB Consensus. Post this, if the automatic generation of the device reflects DES (CE/FDA marked) on the opted platform, then the patient is enrolled in this arm of the RCT

    Device: Drug Eluting Stent

Interventions

  • DeviceProtégé and Protégé NC

    Protégé Drug-eluting PTCA Balloon Catheters are rapid exchange catheters with a semi-compliant (Protégé DEB) balloon, or a non-compliant (NC) balloon (Protégé NC DEB), both with paclitaxel coating. Protégé is certified and CE marked.

  • DeviceAgent

    The AgentTM Paclitaxel-Coated Balloon Catheter (AgentTM DCB) is a monorail, semi-compliant PCI catheter. Agent™ PCB is CE and FDA certified and approved for clinical use both in Europe and in the US.

  • DeviceDrug Eluting Stent

    Drug Eluting stents is a standard of care treatment for narrowed coronary arteries of the patients

06

What researchers measure

Primary outcomes

  1. Device oriented composite endpoint (DOCE)

    1. Cardiac death 2. New target vessel - related myocardial infarction (TV-MI) 3. Ischemia-driven target-lesion revascularization (TLR)

    Time frame: 24 months

Secondary outcomes

  1. Patient oriented composite endpoint (POCE)

    1. All-cause death 2. Any Stroke 3. All new MI (TV and non-TV related) 4. Unplanned ischemia-driven repeat revascularization

    Time frame: 1 month, 6 month, 12 month, 18 month, 24 month

  2. Additional outcomes

    Total no of events in 1380 patients will be analysed- 1. Definite or probable vessel (stent) thrombosis 2. Ischemia-driven target-vessel revascularization (TVR) 3. Major bleeding (BARC type 3 to 5)

    Time frame: 1 month, 6 month, 12 month, 18 month, 24 months

Other outcomes

  1. All individual components of DOCE and POCE

    Total no of events in 1380 patients will be analysed - 1. All-cause death 2. Cardiac death 3. Any Stroke 4. All new MI (TV and non-TV related) 5. Ischemia-driven TLR 6. Unplanned ischemia-driven repeat revascularization

    Time frame: 1 month, 6 month, 12 month, 18 month, 24 month

  2. Other outcomes of interest

    Device success: Defined as the ability of the study devices to be delivered, dilated and retrieved from the target lesion during index procedure.

    Time frame: 0 day (during index PCI)

  3. Other outcomes of interest

    Procedure duration, radiation exposure and contrast volume.

    Time frame: 0 day (during index PCI)

  4. Other outcomes of interest

    Procedural success: Achievement of a final diameter stenosis of \< 30% (site-reported) using any PCI method, without the occurrence of death, MI or repeat vessel revascularization during index- hospital stay.

    Time frame: 7 days

  5. Other outcomes of interest

    Acute or subacute vessel closure/thrombosis: diameter stenosis of 100% and/or TIMI flow grade 0.

    Time frame: 7 days

  6. Other outcomes of interest

    Periprocedural myocardial injury within 48 hours (according to SCAI definition): Elevated CK-MB of \>10 times upper limit of normal, or cTn (T or I)\>70 times upper limit of normal within 48 hours from the procedure. If cardiac biomarker levels are elevated before the procedure, these levels will be used as the reference instead of normal values.

    Time frame: 2 days

  7. Other outcomes of interest

    Length of In-hospital stay (number of days)

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Luzerner Kantonsspital Spitalstrasse, 6000 Luzern 16, Switzerland
    Lucerne, Canton of Lucerne 6000 Luzern 16, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Investigators do not plan to share individual participant data. However, an overall study data and it's publication results shall be uploaded upon completion of this project at Ct.Gov.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 24 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 9, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07397845
Lead sponsor
Translumina GmbH
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Apr 22, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Dr Brijesh Mishra, PhD
Contact
drbrijeshmishra@translumina.in
+919654596737
Deepanshi Thakur, MSc
Contact
deepanshithakur@translumina.in
Prof. Dr. Florim Cuculi, MD
principal investigator · Cardiology Division Heart Center - Luzerner Kantonsspital Spitalstrasse, 6000 Luzern 16, Switzerland
Prof. Dr. Adnan Kastrati, MD PhD
study chair · German Heart Center Munich Lazarettstraße 36, 80636 München, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion